https://www.yiliao.com/index.php?action=history&feed=atom&title=%E4%BC%98%E6%8D%B7%E5%A6%A5
优捷妥 - 版本历史
2026-04-18T13:28:41Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E4%BC%98%E6%8D%B7%E5%A6%A5&diff=313250&oldid=prev
223.160.138.166：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-06T06:09:31Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[优捷妥]]([[Imjudo]])</strong>，通用名为<strong>[[曲美木单抗]]([[Tremelimumab]])</strong>，研发代码为<strong>[[CP-675206]]</strong>，是一种全人源化<strong>[[IgG2]]</strong>型单克隆抗体，特异性靶向<strong>[[细胞毒性T淋巴细胞相关抗原4]]([[CTLA-4]])</strong>。作为2026年肝胆肿瘤及肺癌免疫治疗的核心药物，[[优捷妥]]通过阻断[[CTLA-4]]与[[B7]]配体的结合，在T细胞活化的早期启动阶段解除免疫抑制。临床上，其与<strong>[[度伐利尤单抗]]</strong>（[[PD-L1]]抑制剂）联合构成的<strong>[[STRIDE方案]]</strong>（单次高剂量曲美木单抗+常规剂量度伐利尤单抗），已成为晚期<strong>[[肝细胞癌]]([[HCC]])</strong>及<strong>[[非小细胞肺癌]]([[NSCLC]])</strong>的一线治疗标准，显著提升了患者的长期生存获益。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">优捷妥</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Imjudo (Tremelimumab)·点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">Tremelimumab Molecule Targeting CTLA-4</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">靶基因：[[CTLA4]]</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[Entrez]]ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">1493</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]编号</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">2505</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P16410</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约148kDa</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">抗体类型</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">全人源IgG2单抗</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">研发公司</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[阿斯利康]]([[AstraZeneca]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">2026状态</th><br />
<td style="padding: 12px; color: #1e40af;">STRIDE方案核心免疫药</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：阻断CTLA-4信号通路</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[优捷妥]]的作用机制聚焦于免疫应答的早期启动阶段，通过解除T细胞活化的限制性“刹车”来动员免疫系统。<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>启动阶段活化：</strong><br />
[[CTLA-4]]在初始T细胞激活时表达，通过与[[B7]]高亲和力结合来抑制T细胞扩增。[[优捷妥]]竞争性阻断该路径，使[[CD28]]激活性信号占据主导，促进效应T细胞的大规模增殖。</li><br />
<li style="margin-bottom: 12px;"><strong>IgG2 骨架优势：</strong><br />
与[[IgG1]]型的[[伊匹木单抗]]不同，[[优捷妥]]采用[[IgG2]]亚型，在阻断受体的同时几乎不介导抗体依赖性细胞毒性（[[ADCC]]），减少了对活化T细胞的直接杀伤，从而更温和地启动免疫反应。</li><br />
<li style="margin-bottom: 12px;"><strong>STRIDE 动力学：</strong><br />
2026年药理研究证实，单次高剂量[[优捷妥]]（[[300mg]]）能产生“免疫冲击”，在诱导充足的克隆多样性后，由[[度伐利尤单抗]]接力维持，实现了强效与耐受性的平衡。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026临床适应症与循证证据</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">疾病领域</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">2026推荐方案(STRIDE)</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">临床产出(试验代号)</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">晚期[[HCC]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">单次[[300mg]]曲美+每4周度伐。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[HIMALAYA]]：三年生存率显著提升。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">转移性[[NSCLC]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[优捷妥]]联合度伐及化疗。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[POSEIDON]]：针对驱动基因阴性者。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[恶性间皮瘤]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">双免疫联合方案。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[NCCN]]2026：作为难治性患者的可选方案。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026治疗策略：STRIDE Regimen 与安全性管理</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[优捷妥]]在2026年的临床使用中，强调“单次冲击”带来的独特免疫获益与风险管控：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>给药模式创新：</strong> 传统的[[CTLA-4]]方案常因多剂次给药导致严重毒性。[[优捷妥]]通过STRIDE方案，仅在第一周期给药一次，既大幅降低了累积毒性，又保留了免疫启动效应。</li><br />
<li style="margin-bottom: 12px;"><strong>特异性 irAE 管理：</strong> 重点关注<strong>[[免疫性肠炎]]</strong>、<strong>[[皮肤毒性]]</strong>及<strong>[[垂体炎]]</strong>。2026版指南强调，对于接受单次[[300mg]]冲击的患者，应在前8周内密切监测腹泻及内分泌指标。</li><br />
<li style="margin-bottom: 12px;"><strong>围手术期探索：</strong> 2026年前沿研究正探讨[[优捷妥]]在肝癌新辅助治疗中的潜力，利用单次免疫启动促进术前病理完全缓解([[pCR]])。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[CTLA-4]]：</strong> 免疫系统的第一道刹车，[[优捷妥]]的结合靶标。</li><br />
<li style="margin-bottom: 8px;"><strong>[[STRIDE方案]]：</strong> 优捷妥联合度伐利尤单抗的特定给药模式。</li><br />
<li style="margin-bottom: 8px;"><strong>[[度伐利尤单抗]]([[英飞凡]])：</strong> [[优捷妥]]的最佳免疫搭档（[[IO+IO]]组合）。</li><br />
<li style="margin-bottom: 8px;"><strong>[[HIMALAYA研究]]：</strong> 奠定[[优捷妥]]在晚期肝癌一线地位的关键III期临床。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Abou-Alfa GK,et al.(2022/2026Update).</strong> <em>Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.</em> <strong>[[The New England Journal of Medicine]]</strong>.<br><br />
<span style="color: #475569;">[权威点评]：STRIDE方案通过单次300mg冲击实现了肝癌生存曲线的长尾效应，具有划时代的科学价值。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>[[AstraZeneca]] Oncology R&D(2025/2026).</strong> <em>Long-term safety and efficacy of Imjudo across global patient populations.</em> [Academic Review]<br><br />
<span style="color: #475569;">[学术点评]：2026年汇总分析确认，[[优捷妥]]在跨癌种联合方案中展现了极高的临床稳定性和安全性平衡。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
优捷妥 (Imjudo) · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[CTLA-4]]•[[PD-L1]]•[[CD80/86]]•[[CD28]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">核心方案</td><br />
<td style="padding: 10px 15px; color: #334155;">[[STRIDE Regimen]]•[[POSEIDON方案]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联疾病</td><br />
<td style="padding: 10px 15px; color: #334155;">[[肝细胞癌]]•[[非小细胞肺癌]]•[[小细胞肺癌]]•[[恶性间皮瘤]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">竞争药物</td><br />
<td style="padding: 10px 15px; color: #334155;">[[易普利姆玛]]•[[瑞拉利单抗]]([[LAG-3]])•[[卡博替尼]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.166